SPOTLIGHT -
Rejoyn: A Fundamental Change in How Clinicians Can Treat MDD Symptoms
Rejoyn was recently cleared by the FDA, making it the first prescription digital therapeutic for major depressive disorder.
TAAR1 and the Future of MDD Treatment
New research explores ulotaront as an adjunctive therapy for adults with major depressive disorder.